• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

September 2013

Summary View

ADVERSE REACTIONS

Postmarketing Adverse Reactions
  • added ... dysphonia and gastroesophageal reflux disease